Skip to main content

Table 2 (Abstract O7). Treatment-related safety events

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Patients, n (%)

Urelumab monotherapy N=23

Urelumab + nivolumab N=104

Treatment-related AEs

65 (53)

65 (53)

Most frequent treatment-related AEsa

  

Fatigue

18 (15)

27 (26)

AST increased

16 (13)

9 (9)

ALT increased

12 (10)

13 (13)

Treatment-related grade ¾ AST elevation

4 (3)

3 (3)

Treatment-related ¾ ALT elevation

3 (2)

3 (3)

Treatment-related serious AEs

9 (7)

10 (10)

Treatment-related AEs leading to discontinuation

6 (5)

7 (7)

Treatment-related deaths

0

0

  1. AE, adverse event; AKT, alanine aminotransferase; AST, aspartate aminotransferase.
  2. aTreatment-related AEs occurring in ≥10% of all patients
Back to article page